Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selection of T1249-resistant human immunodeficiency virus type 1 variants.

Journal of virology - 1 Jul 2008

Eggink Dirk, Baldwin Christopher E, Deng Yiqun, Langedijk Johannes P M, Lu Min, Sanders Rogier W, Berkhout Ben

Abstract excerpt

Human immunodeficiency virus type 1 (HIV-1) entry is an attractive target for therapeutic intervention. Two drugs that inhibit this process have been approved: the fusion inhibitor T20 (enfuvirtide [Fuzeon]) and, more recently, the CCR5 blocker maraviroc (Selzentry). T1249 is a second-generation fusion inhibitor with improved antiviral potency compared to the first-generation peptide T20. We selected...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Circular Dichroism
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to HIV Envelope Protein gp41

Share to HIV Fusion Inhibitors

Share to Inhibitory Concentration 50

Share to Peptide Fragments

Share to Ultracentrifugation

Share to Virus Internalization

Source

Open in PubMed Open full text

Identifiers

PMID: 18434391
DOI: 10.1128/JVI.00352-08
PMCID: PMC2447091

Genes

CCR5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selection of T1249-resistant human immunodeficiency virus type 1 variants.PMID 18434391Read ↗

Human immunodeficiency virus type 1 variants resistant to first- and second-version fusion inhibitors and cytopathic in ex vivo human lymphoid tissue.Semantic proximity Read ↗

Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function.Semantic proximity Read ↗

Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors.Semantic proximity Read ↗

Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.Semantic proximity Read ↗

Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization.Semantic proximity Read ↗

Resistance and replicative capacity of HIV-1 strains selected in vivo by long-term enfuvirtide treatment.Semantic proximity Read ↗

Resistance profiles of novel electrostatically constrained HIV-1 fusion inhibitors.Semantic proximity Read ↗

In vitro selection and characterization of HIV-1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor.Semantic proximity Read ↗

Emergence of a Drug-Dependent Human Immunodeficiency Virus Type 1 Variant during Therapy with the T20 Fusion InhibitorSemantic proximity Read ↗

Characterization of Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein Variants Selected for Resistance to a CD4-Mimetic Compound.Semantic proximity Read ↗

Characterization of human immunodeficiency virus (HIV-1) envelope glycoprotein variants selected for resistance to a CD4-mimetic compoundSemantic proximity Read ↗

Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.